Our blog: China’s technology, consumer and new retail insights
We’ve written a lot of articles on a variety of topics that can benefit everyone from a complete beginner to experienced marketers. Do a search for a specific topic of interest or read them in sequence for a broader view. It’s up to you.
LATEST CHINA MARKETING AND CONSUMERS INSIGHTS
Jiuquan Satellite Launch Center: China’s Desert Spaceport
The Jiuquan Satellite Launch Center is a Chinese spaceport in the Gobi Desert, in the border region of Gansu and Inner Mongolia. It supports astronaut missions, satellite launches, and commercial rocket development. Its wider launch area brings national space programs and commercial operators into the same regional aerospace network. That combination makes Jiuquan relevant beyond […]
Geespace: Geely’s Satellite Network for Connected Mobility
Geespace is Geely Holding’s satellite communications business. It develops and operates GEESATCOM, the low Earth orbit network associated with the Geely Future Mobility Constellation, to connect vehicles and industrial equipment beyond terrestrial mobile coverage. Its commercial value is keeping essential information moving when a cellular connection disappears. The project offers a concrete example of China […]
Mobility as a Service in China: Platforms and Integration
MaaS (mobility as a service) connects transport modes through coordinated journey planning, access, and payment services. In China, city transport systems work with consumer platforms to make those connections usable in everyday travel. The commercial question is how much of the journey a platform can actually coordinate. Route recommendations, valid transit tickets, and revenue-sharing agreements […]
GalaxySpace: China’s LEO Satellite Manufacturing Strategy
GalaxySpace is a Chinese satellite manufacturer and satellite internet technology provider. Its low Earth orbit (LEO) strategy combines repeatable spacecraft production, internally developed communications hardware, and network validation with telecom partners. The commercial significance lies in its attempt to make advanced satellites practical to manufacture, deploy, and integrate into customer operations. Its portfolio spans complete […]
Pharmaron: Drug R&D Infrastructure From Discovery to Clinic
Pharmaron is a China-based provider of drug research, development, and manufacturing services. It combines a contract research organization (CRO) with a contract development and manufacturing organization (CDMO), supporting pharmaceutical and biotechnology clients through discovery, preclinical testing, and clinical development. Its service portfolio covers small molecules, biologics, and cell and gene therapies. Its importance lies in […]
CNSA: China’s Space Agency, Policy and Exploration Strategy
CNSA, the China National Space Administration, is China’s national space agency responsible for areas including civil space policy, exploration programs, and international cooperation. Its work connects scientific missions with industrial development, including dedicated oversight of commercial space. China’s space progress offers a useful view of how the country develops complex technologies and organizes research partnerships. […]
WuXi AppTec: China’s Integrated Drug R&D Services Engine
WuXi AppTec is headquartered in China and provides drug discovery, preclinical research, process development, and manufacturing services. Its contract research, development, and manufacturing organization (CRDMO) model supports pharmaceutical companies as they turn experimental molecules into medicines. The business matters because promising science needs reproducible production, reliable testing, and usable regulatory documentation. Its capabilities offer a […]
Legend Biotech: CAR-T, CARVYKTI and Cell Therapy Scale
Legend Biotech has grown from a Nanjing startup into what the company describes as the world’s largest standalone cell therapy company, with more than 10,000 patients treated with CARVYKTI as of December 2025. The company reported $1.9 billion in CARVYKTI net trade sales for full-year 2025 and achieved franchise profitability, a milestone that few biotech […]
Insilico Medicine: Generative AI From Target to Clinic
Insilico Medicine is a global biotechnology company that uses generative AI to identify disease targets, design molecules, and advance drug candidates into human trials. Its lead candidate, rentosertib, reached Phase III patient dosing in September 2026. The company offers a concrete case study of AI moving into pharmaceutical development, with China playing an important role […]
GenScript: From Gene Synthesis to Biologics Infrastructure
GenScript is a biotechnology group that supplies gene synthesis, protein and antibody research services, and drug development and manufacturing support through ProBio. Its portfolio also includes industrial enzymes through Bestzyme. It sells the picks and shovels of biotech: genes to order, proteins on demand, and factory capacity to make them at scale. The company offers […]
Mindray: How China Built a High-End Medtech Challenger
Mindray is a Chinese medical technology company headquartered in Shenzhen, and its recent progress shows why China’s high-end medtech sector deserves closer study. The company now competes across patient monitoring, ultrasound, diagnostics, anesthesia, critical care, surgery, and connected hospital technology. In the first half of 2026, international business generated 53% of company revenue and grew […]
BeiGene Is Now BeOne Medicines: From Chinese Roots to Global Oncology Scale
Is BeiGene a Chinese company? The precise answer is: it is China-founded, but today’s corporate structure is global. BeiGene is no longer just a Chinese biotech story. In May 2025, the company completed a redomiciliation to Switzerland and rebranded as BeOne Medicines Ltd., a global oncology company with $5.3 billion in full-year 2025 revenue, a […]